Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218783 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
A Phase 3 study of Glaucoma and Cataract, sponsored by SpyGlass Pharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT07218783: Recruiting Phase 3 study of Glaucoma and Cataract, sponsored by SpyGlass Pharma.
NCT07218783 is a Phase 3 study of Glaucoma and Cataract that is actively recruiting participants, run by SpyGlass Pharma. The registered enrollment target is 400 participants, below the 906-participant average among 92 other Glaucoma trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07218783, a Phase 3 study of Glaucoma and Cataract, is actively recruiting participants, sponsored by SpyGlass Pharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.
Primary Outcome
Time-matched mean IOP change from Baseline in the study eyes at all the individual IOP timepoints
Conditions Studied
Interventions
- DRUG Bimatoprost Implant System
- DEVICE SpyGlass IOL
- DRUG Timolol Maleate Ophthalmic Solution, 0.5%
- DEVICE Commercial IOL
Study Locations (1)
Texas
- Houston Eye Associates - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2025-10-15 |
| Est. Completion | 2031-03-31 |
| Phase | Phase 3 |
What NCT07218783 shows while recruiting
NCT07218783 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 906-participant average among 92 other Glaucoma trials with a reported enrollment target (56% lower).
The record links to 3 conditions, with Glaucoma appearing as the primary indexed condition, and to 4 interventions - of which Bimatoprost Implant System is the first listed.
NCT07218783 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07218783 about?
NCT07218783 is a clinical study titled "Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)". This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.
What is the current status of trial NCT07218783?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2025-10-15. Estimated completion is 2031-03-31.
What conditions does trial NCT07218783 study?
This clinical trial studies the following conditions: Glaucoma, Cataract, Ocular Hypertension.
What interventions are being tested in trial NCT07218783?
The interventions under investigation include: Bimatoprost Implant System (DRUG), SpyGlass IOL (DEVICE), Timolol Maleate Ophthalmic Solution, 0.5% (DRUG), Commercial IOL (DEVICE).
Who is sponsoring clinical trial NCT07218783?
This trial is sponsored by SpyGlass Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07218783 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07218783's enrollment target sits among peer trials
400 14th of 92 higher than 78 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilocarpine Use After Kahook Goniotomy
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
COMPLETED · Phase 3
-
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
-
Functional and Structural Imaging for Glaucoma
RECRUITING
-
Topical Insulin for Glaucoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI